^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Colorectal Cancer
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor) +
    Vectibix (panitumumab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The NCCN Panel recommends three drug combinations as subsequent treatment options for patients with mCRC that harbors the BRAF V600E mutation:...2) dabrafenib, trametinib, and cetuximab or panitumumab…
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Clin Oncol
    Title:

    Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)

    Excerpt:
    Eligible pts with BRAFm mCRC received doublet, D+P or T+P, or triplet, D+T+P….The confirmed response rate for D+P was 10% and for D+T+P was 26% (Table 1). Treatment with either regimen reduced levels of pERK in on-treatment biopsies relative to pre-dose biopsies (median reduction D+P 23%; D+T+P 54%).
    DOI:
    10.1200/jco.2015.33.15_suppl.103
    Trial ID:
    NCT01750918